Ovid Therapeutics (OVID) Competitors

REGENXBIO (NASDAQ:RGNX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Is RGNX or OVID more profitable?

REGENXBIO has a net margin of -112.70% compared to Ovid Therapeutics' net margin of -574.44%. Ovid Therapeutics' return on equity of -58.87% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.70%	-66.95%	-34.14%
Ovid Therapeutics	-574.44%	-58.87%	-43.18%

Do analysts prefer RGNX or OVID?

REGENXBIO currently has a consensus target price of $28.38, suggesting a potential upside of 165.43%. Ovid Therapeutics has a consensus target price of $3.10, suggesting a potential upside of 73.18%. Given REGENXBIO's higher probable upside, equities research analysts plainly believe REGENXBIO is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Does the media prefer RGNX or OVID?

In the previous week, Ovid Therapeutics had 18 more articles in the media than REGENXBIO. MarketBeat recorded 24 mentions for Ovid Therapeutics and 6 mentions for REGENXBIO. Ovid Therapeutics' average media sentiment score of 0.93 beat REGENXBIO's score of 0.46 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	15 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, RGNX or OVID?

Ovid Therapeutics has lower revenue, but higher earnings than REGENXBIO. Ovid Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$83.33M	6.48	-$227.10M	-$3.44	-3.11
Ovid Therapeutics	$570K	223.31	-$26.43M	-$0.53	-3.38

Which has more risk & volatility, RGNX or OVID?

REGENXBIO has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.

Do institutionals & insiders believe in RGNX or OVID?

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 12.8% of REGENXBIO shares are held by company insiders. Comparatively, 13.1% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ovid Therapeutics beats REGENXBIO on 9 of the 16 factors compared between the two stocks.